OBG 2026 Updates: Cervical Cancer, Immunization, Contraception, and Screening

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/17

flashcard set

Earn XP

Description and Tags

High-yield vocabulary flashcards reviewing 2026 clinical guidelines in obstetrics and gynecology, covering cervical cancer screening, maternal immunization, Rh prophylaxis, DMPA contraception, postmenopausal bleeding workup, and thalassemia screening.

18 Terms

1
New cards

HPV Vaccination Campaign (India)

A free nationwide campaign launched in Feb 2026 targeting 1.15 crore girls aged 14 years with a single dose of Gardasil-4 (0.5 mL0.5\,\text{mL} IM in the left upper arm).

2
New cards

WHO 90-70-90 Elimination Target

Global cervical cancer targets calling for 90%90\% of girls fully vaccinated by age 15 years, 70%70\% of women screened at 35 and 45 years of age, and 90%90\% of identified women receiving treatment.

3
New cards

ACS 2026 Cervical Screening (21–29 years)

Cervical cytology every 3 years.

4
New cards

ACS 2026 Cervical Screening (30–65 years)

Primary clinician-collected hrHPV every 5 years (preferred). If unavailable, options include co-testing every 5 years, patient-collected hrHPV every 3 years, or cytology every 3 years.

5
New cards

ACS 2026 Cervical Screening (≥65\ge 65 years)

Routine screening is not indicated after adequate prior screening.

6
New cards

Tdap Maternal Immunization (ACOG 2026)

Administered during every pregnancy, preferably at 27–36 weeks of gestation, regardless of previous Tdap vaccination status.

7
New cards

Maternal Influenza Vaccine (ACOG 2026)

Inactivated or recombinant vaccine that can be given in any trimester during the influenza season.

8
New cards

Maternal COVID-19 Vaccine (ACOG 2026)

Vaccine that can be given in any trimester and should be administered as soon as possible.

9
New cards

RSV Vaccine (Pfizer Abrysvo)

Maternal immunization administered at 32%-36 weeks during the seasonal window (give ASAP).

10
New cards

Anti-D Immunoglobulin (<20< 20 weeks)

Rh-D Ig dose of 150 μg150\,\mu\text{g} given after a sensitizing event occurring before 20 weeks of gestation.

11
New cards

Anti-D Immunoglobulin (After 20 weeks)

Rh-D Ig dose of 300 μg300\,\mu\text{g} given after a sensitizing event at or after 20 weeks of gestation (give ASAP; if delayed >72 h> 72\,\text{h}, up to 10 days).

12
New cards

DMPA-SC

Subcutaneous depot medroxyprogesterone acetate formulated as 104 mg/0.65 mL104\,\text{mg} / 0.65\,\text{mL} (Antara-SC/Sayana Press) that is self-administrable.

13
New cards

DMPA-IM

Intramuscular depot medroxyprogesterone acetate formulated as 150 mg150\,\text{mg} (Antara).

14
New cards

Postmenopausal Bleeding Initial Evaluation (ACOG 2026)

The standard evaluation recommended for most patients with postmenopausal bleeding, consisting of transvaginal sonography (TVS) combined with endometrial tissue sampling.

15
New cards

TVS Without Biopsy Protocol in PMB

Protocol used initially only when all conditions are met: single episode of PMB, endometrium fully visualized, endometrial thickness ≤4 mm\le 4\,\text{mm}, no strong risk factors for endometrial cancer, and prompt gynecologic follow-up available.

16
New cards

Strong Risk Factors for Endometrial Cancer

High-risk clinical factors in PMB including exogenous estrogen, SERM (e.g., Tamoxifen), BMI >30> 30, nulliparity, Lynch/Cowden/family history, Black race, and diabetes mellitus.

17
New cards

Project MUKTA

"Mission to Unite and Keep Thalassemia Away"—an Indian screening initiative to detect carriers of β\beta-thalassemia, sickle cell disease, and other Hb variants in all previously untested women, tested ideally before 8 weeks at the first ANC visit.

18
New cards

High-Performance Liquid Chromatography (HPLC) in Project MUKTA

The definitive technique of choice for thalassemia carrier screening, required because red-cell indices and Mentzer index alone are not sufficient for definitive diagnosis.